Showing results (191-200 of 242) with videos related to
Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2024
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung CancerDavid R Spigel, Afshin Dowlati, Yuanbin Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 9, 2019
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium ExperienceBadi El Osta, Madhusmita Behera, Sungjin Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2018
Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung CancerCaroline E McCoach, Anh T Le, Katherine Gowan, et al.The American Journal of Pathology|November 30, 2005
Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine modelRobert S Stearman, Lori Dwyer-Nield, Laura Zerbe, et al.European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanomaTina J Hieken, David Zahrieh, Thomas J Flotte, et al.Cancer Prevention Research (Philadelphia, Pa.)|December 28, 2012
Endobronchial miRNAs as biomarkers in lung cancer chemopreventionCeline Mascaux, William J Feser, Marina T Lewis, et al.Cancer Research|January 21, 2006
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell linesSamir E Witta, Robert M Gemmill, Fred R Hirsch, et al.Journal of the National Cancer Institute|May 5, 2005
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancerFederico Cappuzzo, Fred R Hirsch, Elisa Rossi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancerFred R Hirsch, Marileila Varella-Garcia, Paul A Bunn, et al.Clinical and Translational Science|May 7, 2010
Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinibD Mark Hickinson, Gayle B Marshall, Garry J Beran, et al.Pageof 25